▁reaction - prote ct ive ▁memb rane . ▁The ▁device ▁contains ▁pan cre atic ▁pro gen itor ▁cells ▁that ▁have ▁been ▁differenti ated ▁from ▁emb ry onic ▁stem ▁cells . ▁After ▁surg ical ▁impl ant ation ▁in ▁an ▁out pat ient ▁procedure , ▁the ▁cells ▁m ature ▁into ▁end ocr ine ▁cells ▁which ▁ar range ▁in ▁is let - like ▁clusters ▁and ▁m im ic ▁the ▁function ▁of ▁the ▁pan cre as , ▁producing ▁ins ul in ▁and ▁gl uc agon . ▁The ▁technology ▁advanced ▁from ▁pre - cl in ical ▁studies ▁to ▁F DA ▁appro val ▁for ▁phase ▁ 1 ▁clin ical ▁tri als ▁in ▁ 2 0 1 4 , ▁and ▁presented ▁two - year ▁data ▁from ▁the ▁trial ▁in ▁June ▁ 2 0 1 8 . ▁They ▁reported ▁that ▁their ▁product , ▁called ▁P EC - En cap , ▁has ▁so ▁far ▁been ▁safe ▁and ▁well ▁toler ated ▁in ▁patients ▁at ▁a ▁do se ▁below ▁th era pe ut ic ▁levels . ▁The ▁enc aps ulated ▁cells ▁were ▁able ▁to ▁surv ive ▁and ▁m ature ▁after ▁impl ant ation , ▁and ▁imm une ▁system ▁re jection ▁was ▁decre ased ▁due ▁to ▁the ▁protect ive ▁memb rane . ▁The ▁second ▁phase ▁of ▁the ▁trial ▁will ▁evaluate ▁the ▁effic acy ▁of ▁the ▁product . ▁Via Cy te ▁has ▁also ▁been ▁receiving ▁financial ▁support ▁from ▁J DR F ▁on ▁this ▁project . ▁ ▁In iti atives ▁around ▁the ▁glo be ▁In ▁the ▁United ▁States ▁in ▁ 2 0 0 6 , ▁J DR